Yale School of Medicine

Research Studies at Yale

Research Studies at Yale

N-Methyl-D-Aspartate (NMDA) Dysregulation in Individuals With a Family Vulnerability to Alcoholism

For Patients For Researchers

Condition: Alcoholism

What is the purpose of this trial?

The proposed study is the first to explore the contribution of brain glutamate systems, a major target of ethanol in the brain, to the vulnerability to develop alcoholism. This study may lead to an enhanced understanding of the underlying neurobiological mechanism in high-risk individuals that may lead to the transition from moderate to excessive use of alcohol.


Dates: March 2001 -
Study Status: Recruiting

Who can participate?

Ages Eligible: 21 Years - 30 Years
Gender Eligible: Both
This trial accepts healthy volunteers

Inclusion Criteria:

  1. Male and female between the ages of 21 and 30 years
  2. Medically and neurologically healthy on the basis of history, physical examination, EKG, Screening laboratories, absence of current and/or past substance abuse
  3. For Family History Positive (FHP) Subjects: Biological father and another first or second-degree biological relative with history of alcoholism

Exclusion Criteria:

  1. DSM-IV psychiatric and substance abuse diagnosis by history on psychiatric evaluation that includes a structured diagnostic interview (The Semi-Structured Assessment for the Genetics of alcoholism: SSAGA) and the Wisconsin Scales of Psychosis Proneness
  2. history of counseling or psychotherapy; except family therapy centered around another family member
  3. extended unwillingness to remain alcohol-free for three days prior to testing and for the duration of the testing period
  4. for women: positive pregnancy test at screening or intention to engage in unprotected sex during the study
  5. alcohol naïve.
  6. previous bad experience with ketamine.
  7. Adoptee and no contact with family members.
  8. For Family History Negative (FHN) Subjects: NO family history of alcoholism in any first or second-degree relatives. Subjects must reliably report on three first-degree relatives.

Sponsor: Yale University

First Received: December 27, 2007 
Last Updated: Feb 04, 2009
Clinicaltrials.gov ID: NCT00588952
Study HIC # 0103012310

Condition: Alcoholism

What is the purpose of this trial?

The proposed study is the first to explore the contribution of brain glutamate systems, a major target of ethanol in the brain, to the vulnerability to develop alcoholism. This study may lead to an enhanced understanding of the underlying neurobiological mechanism in high-risk individuals that may lead to the transition from moderate to excessive use of alcohol.


show additional information...

Dates: March 2001 -
Study Status: Recruiting

Who can participate?

Ages Eligible: 21 Years - 30 Years
Gender Eligible: Both

Inclusion Criteria:

1. Male and female between the ages of 21 and 30 years

2. Medically and neurologically healthy on the basis of history, physical examination,
EKG, screening laboratories, absence of current and/or past substance abuse

3. For Family History Positive (FHP) Subjects: Biological father and another first or
second-degree biological relative with history of alcoholism

Exclusion Criteria:

1. DSM-IV psychiatric and substance abuse diagnosis by history on psychiatric evaluation
that includes a structured diagnostic interview (The Semi-Structured Assessment for
the Genetics of alcoholism: SSAGA) and the Wisconsin Scales of Psychosis Proneness

2. History of counseling or psychotherapy; except family therapy centered around another
family member

3. Extended unwillingness to remain alcohol-free for three days prior to testing and for
the duration of the testing period

4. For women: positive pregnancy test at screening or intention to engage in unprotected
sex during the study

5. Alcohol naïve

6. Previous bad experience with ketamine

7. Adoptee and no contact with family members

8. For Family History Negative (FHN) Subjects: NO family history of alcoholism in any
first or second-degree relatives (subjects must reliably report on three first-degree
relatives)


Additional Location

Connecticut

Sponsor: Yale University

First Received: December 27, 2007 
Last Updated: Feb 04, 2009
Clinicaltrials.gov ID: NCT00588952
Study HIC # 0103012310

Participate in this trial

For more information about this trial, contact:

Diana D. Limoncelli, BA
203-932-5711 Ext. 5217
arc1@yale.edu


Yale Researcher

Petrakis, Ismene Leonida
Principal Investigator  

HIC # 0805003779